Top Stories
The ECG2Stroke model was trained and validated on data from more than 200,000 patients.
Up to 71% of clinically significant lung nodules lack appropriate follow-up, while high-risk pulmonary embolism patients can face treatment delays.
The pharma will use Tempus' Lens platform to pressure-test trial assumptions and stratify patient groups across five initial programmes spanning solid tumours and Alzheimer's disease.
Partnership targets speedier development of vaccines and therapies, as well as disease forecasting and health-system planning in lower-income countries.
The companies expect the initiative to test roughly 7000 breast and lung cancer patients annually.
Conference News
STOCKHOLM, May 15, 2026 /PRNewswire/ -- United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare solutions, unveiled its comprehensive portfoli...
Ahead of ASCO 2026, Phesi president warns that “flaws are being scaled, not solved” as AI tools rely on historical protocol templates without patient data or contextBoston, USA, 13 May 2026. Phesi, a ...
Data highlight advancements across ElevateBio's targeted gene insertion platform, powered by retrotransposon and machine learning-optimized recombinase approaches, and its new epigenetic editing platf...
Thu, May 14, 2026 12:41 CETReport this content Lioness Medtech AB (publ) will be exhibiting at ESTRO (European Society for Radiotherapy and Oncology) 2026, taking place from 15-18 May 2026 at Stockhol...
Research explores evolving treatment patterns, data quality and equity in community careBOSTON & PHILADELPHIA--(BUSINESS WIRE)-- Ontada®, a McKesson business dedicated to real-world oncology data and ...
